Dysmenorrhea Treatment Market, by Application (Hospital, Pharmaceutical, Clinic), by Type (Primary, Secondary), by Treatment (NSAIDs, Hormonal, Non-steroidal anti-inflammatory drugs, Combined oral contraceptive) – Global Forecast 2027
Globally, more than 50% of post pubescent menstruating women are affected by dysmenorrhea, with 10–12% of them having severe dysmenorrhea with incapacitation for 1–3 days each month. Because young women constitute a significant percentage of the adult work force in the US, nearby 600 million working hours or 2 billion dollars are lost annually because of incapacitating dysmenorrhea if adequate relief is not provided. Women who continue to work or to attend classes have been shown to have lower work output or scores during their dysmenorrhea.
Dysmenorrhea is characterized as recurrent pelvic pain associated with menstruation. Dysmenorrhea is the most well-known gynecologic dissension in adolescents, happening in 60-93% of ladies in this demographic congregation. It is more predominant amid late youthfulness, with the start of ovulatory cycles a few years after the beginning of menstruation. Crest occurrence happens amid the late adolescent years and mid-20s.
Request for sample report at https://www.marketresearchfuture.com/sample_request/727 .
The Dysmenorrhea is been treated by various methods such as with the help of medicines, with the help of high level treatment and in some severe cases surgeries is been preferred. Presently Transcutaneous electrical nerve stimulation (TENS) device is been used for the treatment of Dysmenorrhea.
Rising prevalence of dysmenorrhea, high consciousness level and growing concern about dysmenorrhea among females, contribution of companies for developing advanced treatments, and government campaigns with respect to women healthcare are effectively sanctioning the growth of dysmenorrhea treatment market.
However, consequence and complications of long term treatment, extensive morbidity of dysmenorrhea which leads to inadequate treatment, and traditional values of families would hinder the growth of dysmenorrhea treatment market.
Browse Complete Report at https://www.marketresearchfuture.com/reports/dysmenorrhea-treatment-market .
The Global Dysmenorrhea Treatment Market can be segmented on the basis of types, treatment, and applications.
Global Dysmenorrhea Treatment Market by Types:
- Primary and
Global Dysmenorrhea Treatment Market by Treatment methods:
- General Diagnosis
- Non-hormonal medical treatment
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Over-the-counter (OTC) medications
- Hormonal medical treatment
- Combined oral contraceptive
- Progestin regimens
- Levonorgestrel intrauterine system (LN-IUS)
- Surgical Treatment
Global Dysmenorrhea Treatment Market by Applications:
Global Dysmenorrhea Treatment Market Regional Analysis:
The regional analysis includes North America, Europe, Asia Pacific, Middle East and rest of the world.
The Global Dysmenorrhea Treatment Market is expected to grow with a CAGR of more than 3% during the forecasted period due to high usage of low price OTC (over-the-counter) and off-label treatment.
The North America is dominating the Dysmenorrhea market followed by Europe due the existence of a large number of Dysmenorrhea patients in these regions. North America and European Dysmenorrhea market is driven by high healthcare spending, improved healthcare infrastructure and high awareness about the disease and high availability of its treatments.
Asia-Pacific is expected to have rapid growth in Dysmenorrhea market due to increase in purchasing power, changing healthcare infrastructure and increased awareness for clinical facilities in the regions such as India, China, Japan and others. Support of government and non-profit organizations in awareness campaigns is enhancing the Dysmenorrhea market by creating awareness about the disease, its symptoms and various treatments available, in the mind of the consumers.
Latest Trends in Dysmenorrhea Treatment Market:
- Novartis receives three FDA Breakthrough Therapy Designations in 2016 for Ilaris to treat rare types of Periodic Fever Syndromes.
- Transcutaneous electrical nerve stimulation (TENS) is an established method for pain relief in Dysmenorrhea, which does not involve the use of medication.
Global Dysmenorrhea Treatment Market Major Players:
Some of the major players of Global Dysmenorrhea Treatment Market are as follows: Novartis Pharmaceuticals Corporation, Merck, Inc., Bayer Schering Pharma AG, Vanita Therapeutics, Alvogen, Pfizer, Inc., Roche Laboratories, Taj Pharmaceuticals, Ltd., Sanofi, Terramedic, Inc., and others.
The reports also cover brief analysis of Geographical Region which includes:
- North America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- Rest of Asia
- Pacific Countries
- New Zealand
- The Middle East& Africa
The report on Dysmenorrhea Market comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance.
This report will provide the clear picture of current market scenario of Dysmenorrhea market globally as well as the country level markets. The report also provides the information about Dysmenorrhea, its various types and treatment method available which are used to cure the disease and it also depict Dysmenorrhea various applications in detail. It will also depict detailed information about companies with their market dynamics involved in manufacturing of pharma products and medicines to treat Dysmenorrhea.
Market Research Future
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312